Latest Content

Honoring the Memory of Surviving After Cancer

January 16th 2025, 6:00pm

By Mike Verano

Article

Fifteen years after my own cancer journey, I find myself balancing hope and grief as I support a colleague newly diagnosed with cancer.

Surgery May Extend Survival For Patients with GIST and Liver Metastases

January 16th 2025, 4:00pm

By Alex Biese

Article

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

HT-001 Addresses Skin Toxicities in Patients With Cancer

January 16th 2025, 2:00pm

By Ryan Scott

Article

In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy results in the CLEER-001 trial

The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care

January 15th 2025, 10:00pm

By Ryan Scott

Article

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.

Polycythemia Vera: Treatment Options

January 15th 2025, 9:37pm

By Julie Huynh-Lu, P.A.

Video

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection based on individual risk factors and symptoms, while patients can actively participate in their care through lifestyle modifications and regular monitoring of blood counts, symptoms and cardiovascular risk factors to achieve both immediate symptom relief and long-term disease control.

Most Cures to Cancer Shared on TikTok Are Fake, Research Shows

January 15th 2025, 8:00pm

By Alex Biese

Video

Findings show that 81% of posts related to cancer on the social media platform TikTok touted fake cures.

Finding Strength Through Faith and Positivity During Cancer

January 15th 2025, 6:00pm

By Carla Deschamps

Article

I share how faith, positive affirmations and resilience helped me overcome stage 2 colon cancer and find strength in recovery.

Machine Learning Predicts Gleevec Nonadherence in Patients With GIST

January 15th 2025, 4:00pm

By Ryan Scott

Article

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.

Elinzanetant May Treat Hot Flashes Caused by Breast Cancer Treatment

January 15th 2025, 2:00pm

By Spencer Feldman

Article

Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.

FDA Grants Priority Review to Sunvozertinib for EGFR Exon20+ NSCLC

January 14th 2025, 10:00pm

By Alex Biese

Article

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

Expert Expands on Side Effects Related to ADC Treatment in Breast Cancer

January 14th 2025, 8:00pm

By Ryan Scott

Video

Dr. Aditya Bardia shared his insights on what he believes are the top side effects to be aware of when undergoing ADC treatment for breast cancer.

The Waiting Room: An Underappreciated Experience

January 14th 2025, 6:00pm

By Mary Sansone

Article

As a cancer treatment waiting room volunteer, I’ve discovered a unique community of shared experiences and unexpected connections.

The Pros and Cons of Seeking a Second Opinion In Cancer Treatment

January 14th 2025, 4:00pm

By Dr. Mohammad Jahanzeb

Article

An expert explains the importance of getting a second opinion during a cancer journey.

Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma

January 14th 2025, 2:00pm

By Ryan Scott

Article

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

Sasanlimab Improves Event-Free Survival for Some With Bladder Cancer

January 13th 2025, 10:00pm

By Alex Biese

Article

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.